


March 29th-30th, 2011
Shanghai, China

BioPharma China Congress 2011



Gaining Clout, Growing up with the Industry

✓ Co-located with
VacTech 2011

Organized By **JFPS** WE EMPOWER BUSINESS

International Media Partner **华尔街日报** THE WALL STREET JOURNAL. cn.WSJ.com

Official Publication **商业评论** 中文网 www.hbrchina.com 哈佛商学院出版社独家授权

中欧商业评论 CEIBS Business Review | 思 | 维 | 力 | 成 | 就 | 决 | 策 | 力 |

BioPharma China Congress 2011



Gaining Clout, Growing up with the Industry

March 29th-30th, 2011 Shanghai, China

Why You Should Attend?

Under the influence of world financial crisis, the BioPharma market in emerging countries is especially promising. China will become the third largest Pharma market after the U.S. and Japan in the next two years. In 2010, the central government has allocated around 30 billion RMB to support the R&D of new drug and biological products. The 12th Five Year Plan for the BioPharma industry and the reform of the health care system will give new impetus to the development of BioPharma industry.

Although the BioPharma industry in China got a late start, it has posted great gains in the recent years. Yet the local BioPharma industry is in a relatively low-end of the industry chain. Lots of opportunities are to be seized.

The ups and downs of the global BioPharma industry are inevitable and bound to become a key focus of almost all drug companies worldwide, large or small, major or startup. BioPharma China Congress 2011 of JFPS Group will invite near 50 BioPharma leaders and pioneers to bring you the latest trends in the industry which are highly interesting. It is a grand platform for face-to-face communication with R&D, trials and other parts of the BioPharma industry.

Who Should Attend?

- BioPharma
- Biotech
- Hospital
- Research institution
- BioPharma outsourcing
- Law firm, VC/PE and Fund
- Insurance
- Equipment
- Service (Cold chain logistics, IT support, consulting)

Whose Titles are:

- CEO, CSO, VP
- Medical director
- Head of R&D
- Director, preclinical & clinical research
- Head of medical affairs and licensing
- Head of external R&D
- Director of strategic alliance
- Professor, Medical Oncology
- Professor, Department of Neurology



Speakers to be invited

Government and Institution:

Karen Midthun

Director

Center for Biologics Evaluation and Research, FDA

Zihou Yan

Director

Shanghai Institute of Biological Products

Dafang Zhong

Director

Shanghai Center for Drug Metabolism and Pharmacokinetics Research

Bruce Beutler

Chairman

Department of Genetics the Scripps Research Institute

Guoqing Li

Director, Center for Drug Evaluation

SFDA

Rongxing Gan

Director

Shanghai Clinical Research Center

Bob Lowenberg

Professor

HOVON Group

University and Hospital:

Zhinan Chen

Director

Cell Engineering Research Center

The Fourth Military Medical University

Jin Li

Professor/Chairman

Medical Oncology, Fudan University Shanghai Cancer Center

Osamu Nureki

Professor

Department of Basic Medical Sciences, the Institute of Medical Science, the University of Tokyo

Hongbo Xin

VP

Nanchang University

Yajun Guo

Professor

Cancer Research Institute

Second Military Medical University

Sven Skog

Professor

Karolinska University Hospital, Sweden

Si Lok

Professor

Chair of Genomic Medicine

Scientific Director

Genome Research Centre, the University of Hong Kong

Huasheng Xiao

Director

Shanghai Biochip Co. Ltd.

Peiyuan Lin

Senior VP, Discovery Biology

HD Biosciences China

BioPharma & Biotech:

Peng Wang

CSO

Sincere

Rich Tillyer

Senior VP

Discovery and Preclinical Sciences, Merck

Caiwen Jiang

VP, Head of Genzyme R&D Asia

Genzyme Corporation

Yu Zhang

Head

China Discovery Research Sanofi-Aventis

Jian Wang

Director

Beijing Genome Institute (BGI) Shenzhen

Hitto Kaufmann

Director

Upstream Development Boehringer Ingelheim

Tong Zhang

Head

Eli Lilly R&D in China

Min Irwin

Medical Director

BSP BAYER HEALTHCARE

Weizhong Shen

Administrative Vice Chairman

Technical Center of Fosun Pharmaceutical

En Li

Head

NIBR Shanghai, Novartis Institutes for Biomedical Research

Mingqiang Zhang

CTO

Roche R&D Centre China

Jianing Xiang

Director

Chemistry GlaxoSmithKline R&D China

Lily Lee

Senior Vice President, Head

Pharmaceutical R&D Asia, JNJ

Elliott Sigal

Executive Vice President, CSO and President

R&D, BMS

Terje Kalland

Senior VP, Head

Biopharmaceuticals Research, Novo Nordisk

Yuki Moritoki

Professor

Medical Science Dept. Chugai-Pharmaceutical

Avery Ince

Medical Director

MSD China

John G. Cox

Executive VP

Pharmaceutical Operations & Technology, Biogen

Qunsheng Ji

Translational Science Director

AstraZeneca Innovation Center China

Eric Grund

Senior Director

Biopharma Applications, GE Lifescience

George D. Yancopoulos

Executive Vice President

CSO & President

Regeneron Research Laboratories

Lingshi Tan

GM

Pfizer China R&D Center

Richard H. Scheller

Executive VP

Genentech Research & Early Development

Arturo Galvani

Head of the Research Unit

Nerviano Medical Sciences

Shaoxiong Wang

Senior Scientist

Translational Sciences Amgen



Day One

▶ March 29th, 2011 Tuesday

8:30 Registration

Plenary Meeting

9:00 **Session I: Status and trend of the BioPharma industry in home & abroad**

- The WTO impact on the China's BioPharma industry
- Interpretation of The 12th Five Year Plan for the BioPharma industry
- An insight into the government support initiatives to encourage the development of BioPharma industry

9:40 **Session II: How can BioPharma companies balance drug discovery and research outsourcing**

- Effect of BioPharma industry on the regional development
- The business strategies of multinational BioPharma companies in China
- How to avoid the risks in the M&A and restructuring
- Research outsourcing- talent pool for drug discovery

10:20 **Session III: The alternatives for Chinese BioPharma companies - from generic drug to new drug**

- How can Chinese BioPharma companies position themselves well in the globalization of the industry
- New drug vs. generic drug
- To lead the drug discovery, to break through the dilemma of generic drug

11:00 **Session IV: Opportunities and risks of the BioPharma investment**

- Deep analysis into the market development of BioPharma
- Is hi-tech the key to BioPharma investment?
- Is it time to invest the Pharma outsourcing industry?
- Financial and intellectual obstacles to impede the investment

11:45 Lunch



Track I: BioPharma R&D Partnering

14:00 **Session V: Develop the sustainable R&D partnership and the key trends emerging out of the partnering**

- To make the most of the talent pool and other resources in different countries
- The strategic adjustment of investment and partnering of multinational BioPharma companies
- The improvement to adapt to the local R&D strategies

14:30 **Session VI: The dilemma of the conservative R&D mode-Gaining momentum with increasing pressure on the cost cutting**

- The rising R&D cost
- The huge risks in R&D
- Safe R&D approach- focus on the existing mechanism
- Different strategies of R&D modes

15:00 **Session VII: The expiration of core technology patents-Future for generic drugs**

- The expired patent for the heavy bomb drugs, new market structure for BioPharma
- The need to establish the regulation of the generic drugs
- Impact of the rising cost of medical care

15:30 **Session VIII: A flexible technology transfer mechanism to the BioPharma industry**

- The trends of BioPharma drug discovery
- Technology transfer and commercial cooperation
- Technology transfer- crucial approach to improve innovation

16:00 **Panel Discussion: Partnerships in drug discovery between China and global key BioPharma players**

16:45 End of Day One

Track II: BioPharma Trials

14:00 **Session V: Establish effective clinical research partnership**

- Status and trends of clinical trial in Asia
- The long-term cooperation between CROs and research institutions and organizations
- The key to develop clinical trials in the emerging markets
- Scale of available resources for clinical development

14:40 **Session VI: The harmonization of the different regulations of home and abroad in a changing environment**

- FDA policies
- 12th Five Year Plan in China and other key policies
- Plan better strategies to protect the IPR and adapt to the local environment
- Enhance and frame better marketing strategies through an understanding of the regulatory environment in local countries

15:20 **Session VII: BioPharma clinical research outsourcing- another Made-in-China?**

- How can China be reckoned with on the international BioPharma market and achieve the globalization of research outsourcing
- International standard to help BioPharma open an door to the innovation and globalization
- Cultivation of the R&D talent to solve the talent shortage in early drug discovery

16:00 **Session VIII: China- the biggest cluster of CRO in the future**

- The CRO industry in China
- The transformation of global clinical research into the emerging market of China
- Development potential of BioPharma trials- investors' interest

16:45 End of Day One



Day Two

► March 30th, 2011 Wednesday

Track I: BioPharma R&D Partnering

- 09:00 **Session I: Genetic engineering- trends in BioPharma drug development**
- The patent war of genetic engineering technologies
 - Develop the core technology and platform to seize the priority
 - Strengthen original research in drug discovery to possess the independent IPR
- 09:40 **Session II: The golden age for the antibody-based drug**
- The application prospect of target discovery and little side effect
 - To break through the development of antibody-based drug in China
 - To solve the restriction of hi-tech and high cost
- 10:20 **Session III: Diagnostic reagent- the new born of BioPharma industry**
- The breakthrough of diagnostic reagent
 - The polarization of the diagnostic technologies
 - Precaution crucial- the new chance for the diagnostic reagent
 - Impact of the reform of health care system
- 11:00 **Session IV: Blood products that are fueling the growth of the market**
- High profits yet no easy market entry
 - How to solve the scarce resource of blood products
 - Extending of the industry chain of blood products

11:45 Lunch



- 14:00 **Session V: Key technologies of biological preparation and its industrialization**
- Drug R&D and new biological preparation
 - New technologies for biological preparation
 - Long-term mechanism and targeting
- 14:40 **Session VI: Pharmacogenomics- adding to the individual treatment**
- New science, new discovery
 - Application in the early stage clinical research
 - Application in the drug discovery
- 15:20 **Session VII: The R&D of tumor treatment- advancing quality through innovation**
- The R&D trends of antineoplastic agents
 - To improve the cooperation of clinical trial to treat the tumor
 - The future application of RNA interference
- 16:00 **Session VIII: Biomarker and translational medicine**
- The identification and application of biomarkers
 - The new research modes of translation medicine
 - The meaning of establishing translational medicine center in universities and research institutions

16:45 End of Day Conference

Track II: BioPharma Trials

- 09:00 **Session I: The impact of the new drug clinical trial approval and launch process on the R&D stage**
- Supporting early stage preclinical development effort to provide cost-effective drugs
 - How to make the result of clinical trial easier to be approved
 - Different modes of BioPharma trials
 - To find the most suitable CRO to increase the effectiveness
 - The strategy to improve the quality of BioPharma trials
- 09:40 **Session II: The application of DMPK in the preclinical development**
- Latest progress
 - DMPK application screening in early drug discovery
 - New technologies
- 10:20 **Session III: The standardized DOE**
- DOE in the different phases of BioPharma trials
 - Adaptive designs for clinical trial to promote the drug discovery
 - To correctly apply statistical methods in different DOE types
- 11:00 **Session IV: Personnel management in the clinical laboratory management**
- People foremost
 - To arouse the enthusiasm and innovation of clinical trial personnel
 - To enhance the quality of clinical trial personnel


11:45 Lunch



- 14:00 **Session V: Safety assessment of clinical trial in China**
- The restriction of the safety assessment in the pre-approval phase
 - The safety assessment in the post-approval phase
 - To prove whether drug is safe or not in clinical trial as soon as possible
 - The problem and strategies of the safety assessment in BioPharma trials in China
- 14:30 **Session VI: Site selection and effective patient recruitment**
- Site selection and safety
 - Ethics in the clinical trials- patient recruitment
 - The effective management of patient in different phases
- 15:00 **Session VII: Data management and statistical analysis**
- The standard of data management in clinical trial
 - Statistical analysis of data
- 15:30 **Session VIII: Multinational clinical trial of tumor in China**
- China- the emerging market of clinical trial
 - The experiences of multinational clinical trial in China
 - The strategies of multinational clinical trial of tumor in Asia
- 16:00 **Panel Discussion: Best practices of clinical trials in Asia and the world: cases in terms of:**
- Retain and attract talents
 - Site
 - Budget
 - Performance management

16:45 End of Day Conference

BioPharma China



Congress 2011

Gaining Clout, Growing up with the Industry

March 29-30, 2011 Shanghai, China

About JFPS Group

JFPS Group is the leading business performance enhancement company with affiliated partners in U.S., China, UK, Japan, Singapore and Malaysia. As a world-class performance enhancement solution provider, JFPS Group provides business executives with knowledge and skills through conferences, professional trainings, in-house training and consulting services. Every year JFPS Group organizes more than 70 events and works with 10,000+ senior executives from leading companies to improve their strategic decision-making process.

Our success is based on the fact that we constantly research and listen to all industry sectors. Our events and solutions are addressing the issues and concerns raised in the discussion that we have with our client. This helps us to ensure that the business information we provide is timely, cutting-edge and features the best speakers.

Your Contact

Tel: +86 21 5172 0000 **Fax:** +86 21 5172 0088 **Email:** sales@jfpsgroup.com **Website:** www.jfpsgroup.com

Mail: Unit 2007-2010, 20th Floor, Tower 1 Kerry Everbright City No. 218, Tian Mu Road (West) Shanghai, China 200070

March 29th-30th, 2011
Shanghai, China

VacTech 2011

Tech Insight, Bioscience Revolution



✓ Co-located with
BioPharma China Congress 2011

Organized By

International Media Partner

Official Publication





VacTech 2011

Tech Insight, Bioscience Revolution

March 29th-30th, 2011 Shanghai, China

Why You Should Attend?

China, the largest market in the world with the population of 1.4 billion people, has expanded its vaccine market three times and continued with the annual growth rate of 15%. Chinese market has reached the market value of 4.36-billion and is expected to 8 billion in 2012, sourced by a research institute.

There are 43 vaccine manufacturing companies in China till 2010 with the ability to prevent against 26 infectious diseases and produce 41 vaccines. China has ranked as the largest manufacturer and user in the world.

China has little difference in the quantity of vaccine but quality and manufacturing techniques with other developed countries. Chinese government gives high prominence to the R&D and manufacturing of vaccine companies and spares 200 million RMB from the project of Vaccine and Antibody Engineering in '863 Plan' to support the development of vaccine industry, together with 60 million to the manufacturing of the important traditional vaccine and quality improvement.

Great breakthrough has been made in China in the R&D and quality of traditional vaccine and genetic vaccine in its safety and stability. Some vaccines, for example, helicobacter pylori vaccine, rabies vaccine and B-type encephalitis vaccine, have been well received into the global market. China is the first country to successfully invent the SARS vaccine.

Who Should Attend?

- Vaccine Manufacturing Companies
- Vaccine Research Institute
- Key Lab of Universities
- Contract Research Organization (CRO)
- Contract Manufacturing Organization (CMO)
- Biotech Companies
- Lab Equipment Suppliers
- Environment Control Equipments
- Vaccine Manufacturing Equipments
- Bioscience and Analytical Equipments
- Diagnostic and Testing Equipments
- Cold Chain
- Facility Design

Whose Titles are:

- President
- BD Director/Manager
- R&D Director/Manager
- Manufacturing Director/Manager
- Director of R&D Center
- Chief Engineer
- Chief Scientist
- Marketing/Sales Director/Manager



Speakers Confirmed and Invited:

Government, Academy & Organization

Helen Evens

President

GAVI Alliance

Yiming Shao *

Chief Expert

National Center for AIDS/STD Control and Prevention, China CDC

Shuren Zhang

Director

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Philip Minor

Director of Virus Institute

National Institute of Biological Standards and Control (NIBSC), British

Pro Ian David GUST

Professor

University of Melbourne

David Lewis

Director General

St. George's Vaccine Institute

Klaus Cichutek

Director General

Paul Ehrlich Institute

Nico Oudendijk

Director General

Netherlands Vaccine Institute

Magdalena Plebanski

Professor & Head, Vaccine and Infectious Diseases Laboratory

Monash University, Australia

Byoung S. KWON

Endowed Investigator

National Cancer Center, Korea

Zhongtian Qi

Professor

Second Military Medical University

Bin Wang *

Professor

Fudan University

Business Community

Pierre Desmons

R&D Director, China

GSK

Gary Gilliland

Head of Tumor Department

Merck

Nick Zhang

R&D Director

Novartis, China

Dr Jean-Marc Guillaume

Head of Bioprocessing, Research & Development USP

Sanofi Pasteur Vaccines, France

Pingping Li *

Director of Virus Vaccine & P3 Lab

Wuhan Institute of Biological Products

Qingwen Zheng

Director of Virus Vaccine

Chengdu Institute of Biological Products

Xiuxia Guo

Director of Vaccine R&D

Changchun Institute of Biological Products

Zhe Chen

Director of Virus Vaccine

Shanghai Institute of Biological Products

Zheng Huang *

Technical Director

Walvax

Ralf Altmeyer *

Director General

Institut Pasteur Shanghai

Qinglang LI *

R&D Director

Tianyuan Bio-Pharmaceutical Co., Ltd

Jun Gao

VP, R&D

Chengda Bio Co., Ltd

Nikolai Petrovsky *

Chairman and Research Director

Vaxine Pty Ltd/Flinders University

Xuanlin Cui

GM

TianTan Biological Products Co., Ltd

Ronghui Pan *

Manager of Vaccine R&D

Innovax

Yichen Lv

President and CEO

Haikou VTI Biological Research Institute

Noel Barrett

VP, Vaccine R&D

Baxter BioScience, Austria

Emma Ball

Program Director, Influenza

CSL

Bent Jakobsen

Technical Director

Adaptimmune

Martin Bachmann *

Chief Scientific Officer

Cytos

* Confirmed



Day One

March 29th, 2011 Tuesday

Stream One

08:30 Registration

Vaccine World is Coming — An Irresistible Trend to Bioscience!

09:00 **Session One: Status and Trend for Vaccine R&D**

- Status for vaccine R&D in China
- Status for new vaccine R&D
- Progress for vaccine R&D in world's leading biopharma companies

09:40 **Session Two: Technology Innovation—Imperative to Us!**

- Accelerate the progress of technology innovation and manufacturing
- Promote the R&D progress of original vaccine products in China
- Facilitate the R&D and development of therapeutic

10:20 **Session Three: Improve the Coordination of Vaccine R&D and Manufacturing**

- Coordination of the standards and principles between R&D and Manufacturing
- Improve the coordination between researcher and manufacturer
- The practicality of immune mechanism to manufacturing

11:00 **Session Four: Vaccine Safety—Establishment of a Good Public Healthcare System**

- Establish a scientific operation and management system
- Regulate vaccine supply chains
- Efficient management of equipments of vaccination

11:40 Luncheon



Prospect and Discovery for New Generation of Vaccine (Case Studies)

Chapter A: Therapeutic Vaccine Section

14:00 **Session Five: Study and Mechanism of Tumor Vaccine**

- Progress of tumor vaccine
- Immune mechanism of tumor vaccine
- Function of P53 protein

14:40 **Session Six: Development of Diabetes Vaccine**

- Latest development of diabetes vaccine
- Impact on immune system by insulin cells
- Synthesis for polypeptide and active protease

15:20 **Session Seven: Status for Hypertension Vaccine**

- Progress and challenges for hypertension vaccine
- Function for pathogenesis
- Sustainability for step-down

16:00 **Session Eight: Breakthrough in HEV Vaccine**

- Safety and Efficiency
- Result in Phase III Preclinical Trail
- DNA Recombinant Technology in the R&D of HEV Vaccine

16:40 End of Day One

Stream Two

R&D and Manufacturing — PART ONE

14:00 **Session Five: New Vaccine Vector**

- New development for vaccine vector
- Enhance or change the Immune Response
- RNA virus reproduction
- Biosafety for new vaccine vector

14:30 **Session Six: New Adjuvant & Vaccine Delivery System**

- Aluminum adjuvant alternatives and technologies: micro-organisms, natural sources and immunostimulants
- Induction of Th1, Th2 immune response mechanism
- Research of Vaccin Delivery System

15:00 **Session Seven: Conjugate Technology In the Use of New Vaccine**

- R&D of Bacterial polysaccharide Conjugate Vaccine Platform Technology
- Freeze-Dried A, C Meningococcal Polysaccharide Conjugate Vaccine
- Quality Control of Conjugate Vaccines

15:30 **Session Eight: Vaccine Preclinical Research and Clinical Trials**

- Standardization for the process of clinical trials
- Design for vaccine research and experiment
- Organization, analysis and conclusion of data

16:00 **Session Nine: Design and Standardization for Virus and Microorganism**

- Design for the Equipment Room
- Hygienic control, safety and environmental protection
- Site choose and arrangement

16:40 End of Day One



Day Two

March 30th, 2011 Wednesday

Stream One

Prospect and Discovery for New Generation of Vaccine (Case Studies)

Chapter B: Infectious Diseases Section

- 09:00 **Session One: New Discovery for HIV Vaccines**
- Study on the structure of molecular chain
 - Study on TCR's recognition of the infectious cells and cancer cells
 - Recognize the guise of HIV by producing and testing T cells
- 09:40 **Session Two: Progress on the Study of H1N1 Flu Vaccine**
- Improve the efficiency by stimulating the antibody
 - Breakthrough on HA, NA protein
 - Glycosylation's interference to alkaline areas
- 10:20 **Session Three: Breakthrough for HFMD Vaccine**
- Study on EV71 virus inactivated vaccine
 - Study on Immune kit
 - Status on clinical trials
- 11:00 **Session Four: Status for TB Vaccine**
- Regional differentiation for immune-protectionism of BCG
 - Establishment of BCG model
 - Progress on BCG R&D

11:40 Lunch



Stream Two

R&D and Manufacturing — PART TWO

- 09:00 **Session One: Cell Culture in Vaccine R&D and Manufacturing**
- Cell culture and its development
 - Cells in the serum-free medium
 - Risk control of hazardous composition in cell culture medium
- 09:30 **Session Two: Vaccine Purification and Downstream Processing Technology**
- Purification of human recombinant subunit vaccine
 - Vaccine for the purification of human virus vaccine
 - Purification of plasmid for gene therapy
 - Purification of therapeutic virus for human
- 10:00 **Session Three: Vaccine Testing Technology**
- Sensitivity analysis
 - Testing for repeatability
 - Bio-Chip detection
- 10:30 **Session Four: Vaccine Research, Development and Manufacturing Tools**
- Vaccine Fermentation Technology
 - Bioreactor Technology
 - Bioinformatics
- 11:00 **Session Five: Vaccine Storage and Transportation Technology**
- Requirements for cold chain of vaccine storage and transportation vaccine
 - Temperature management
 - Freeze-Dried heat protection vaccine storage

11:40 Lunch



Application of Advanced Technology on R&D and Production

- 14:00 **Session Six: Genetic Engineering Vaccine: Mainstream of Vaccine R&D**
- Advantages and challenges of genetic engineering vaccine
 - Progress on recombination of DNA
 - Resistance to the burst infectious disease, which cannot cultivate pathogens in by means of genetic engineering vaccine
- 14:40 **Session Seven: Innovation of Core Techniques of Genetic Engineering Vaccine**
- Combination between GEV and adjuvant
 - Establishment of antigen and screening technology of pathogen
 - Construct Live attenuated vaccine through GEV
- 15:20 **Session Eight: Application of Nanotechnology on Vaccine R&D**
- Applicability of vaccine category
 - Progress of nanotech on vaccine R&D
 - Prospect and operability of nanotech in the fields of vaccine R&D
- 16:00 **Session Nine: Nanotechnology in the Vaccine Delivery**
- Innovative development in the combination of nanomotors and delivery technology
 - Application on the manufacturing of artificial pore, which can deliver the nano substance through membrane
 - Expansion on the possibility of inducing cells to the specific direction
- 16:40 End of Conference

VacTech 2011



Tech Insight, Bioscience Revolution

March 29th-30th, 2011 Shanghai, China

About JFPS Group

JFPS Group is the leading business performance enhancement company with affiliated partners in U.S., China, UK, Japan, Singapore and Malaysia. As a world-class performance enhancement solution provider, JFPS Group provides business executives with knowledge and skills through conferences, professional trainings, in-house training and consulting services. Every year JFPS Group organizes more than 70 events and works with 10,000+ senior executives from leading companies to improve their strategic decision-making process.

Our success is based on the fact that we constantly research and listen to all industry sectors. Our events and solutions are addressing the issues and concerns raised in the discussion that we have with our client. This helps us to ensure that the business information we provide is timely, cutting-edge and features the best speakers.

Your Contact

Tel: +603-2600 6000 **Fax:** +603-2600 6111 **Email:** joyce.l@jfpsgroup.com **Website:** www.fundsforumchina.com

Mail: Suite 23.03, 23rd Floor, Menara Multi-Purpose Capital Square,
No. 8 Jalan Munshi Abdullah 50100 Kuala Lumpur MALAYSIA